When controlling for other covariates in a multivariable model, we found that higher CDKN2A expression was independently associated with poorer PFS (HR 1.25, 95% CI 1.04–1.49, p = 0.015, Fig. 2h), along with having a WHO grade 2 meningioma, subtotal resection (STR) of the meningioma (instead of gross total resection (GTR)), CDKN2A deletion (homodel/heterodel vs CDKN2A intact/wt), and having a more aggressive molecular/methylation group designation (molecular group (MG) 2–4, MenG C, hypermitotic (HM), or immune-enriched (IE)), relative to reference MG1 cases. The gene discussed is CDKN2A; the disease is meningioma.